Caitong International Asset Management Co., LTD Arcutis Biotherapeutics, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $102 Billion
- Q4 2024
A detailed history of Caitong International Asset Management Co., LTD transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 6,896 shares of ARQT stock, worth $88,130. This represents 0.09% of its overall portfolio holdings.
Number of Shares
6,896
Previous 6,896
-0.0%
Holding current value
$88,130
Previous $96.1 Million
-0.0%
% of portfolio
0.09%
Previous 0.09%
Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
213Shares Held
130MCall Options Held
2.07MPut Options Held
151K-
Jennison Associates LLC12.3MShares$158 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.4MShares$146 Million6.61% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$140 Million2.52% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$112 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$110 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $769M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...